melphalan has been researched along with Iris-Diseases* in 1 studies
1 other study(ies) available for melphalan and Iris-Diseases
| Article | Year |
|---|---|
Heterochromia following intravitreal chemotherapy in two cases.
Intravitreal chemotherapy is recognized as an effective treatment for retinoblastoma with vitreous (and occasionally subretinal) seeding refractory to intravenous or intra-arterial chemotherapy. However, this treatment carries with it the risk of toxicity to both the posterior and anterior segments of the eye, including retinal pigment epithelial mottling, ischemic/hemorrhagic retinopathy, posterior synechia, cataract, scleral necrosis, and focal iris depigmentation. We report 2 cases of iris heterochromia secondary to profound iris stromal depigmentation following intravitreal melphalan and topotecan injections. Topics: Diagnosis, Differential; Drug Therapy, Combination; Female; Humans; Infant; Intravitreal Injections; Iris Diseases; Melphalan; Pigmentation Disorders; Retinal Neoplasms; Retinoblastoma; Tomography, Optical Coherence; Topotecan | 2019 |